Reckitt to pay $1.4 billion to end long-running Indivior probes

Britain's Reckitt Benckiser has agreed to pay up to $1.4 billion to resolve all U.S. federal investigations into the sales and marketing of an opioid addiction treatment by its former prescription pharmaceuticals business Indivior .